I dont disagree on the fundamentals of the company. That's why I still hold. The problem is, IMHO, the spending is out of kilter with short-medium term revenue. I believe the company is rated more as a traditional pharma / medical company rather than previously as a blue-sky biotech and that's why the market is concerned with the disparity between outgoings and incomings.
I would also suggest that a rise from 22c to $4 while not producing a profit, whilst great for you (and possibly a bit lucky) is indicative of speculative behaviour which often results in sharp downgrades when imagined profits never materalise.
Thanks
Quarterly, page-96
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 681 | $17.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.25 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |